WKHS Locations

Clinical Trials

Phase III Study for Ceftazidime - Avibactam (CAZ-AVI) Inpatient trial for patients with Ceftazidime-Resistant Gram-Negative Pathogens from Complicated Urinary Tract Infections or Complicated intra-abdominal infection

Study Title

Phase III Study for Ceftazidime - Avibactam (CAZ-AVI) Inpatient trial for patients with Ceftazidime-Resistant Gram-Negative Pathogens from Complicated Urinary Tract Infections or Complicated intra-abdominal infection

Purpose

To estimate the per-patient clinical response to CAZ-AVI and BAT at TOC in the treatment of selected serious infections caused by ceftazidime-resistant Gram-negative pathogens.

To further evaluate the clinical response to CAZ-AVI and BAT at different visits and in patient subgroups (including entry diagnosis, pathogen, resistance mechanism, and previously failed treatment class)

To estimate the microbiological response to CAZ-AVI and BAT in the treatment of selected serious infections caused by ceftazidime-resistant Gram-negative pathogens

To evaluate the reasons for treatment change and/or discontinuation for CAZ-AVI and BAT

To estimate the 28-day, all-cause mortality among patients treated with CAZ-AVI and BAT

To evaluate the safety and tolerability profile of CAZ-AVI and BAT for the treatment of selected serious infections caused by ceftazidime-resistant Gram-negative pathogens

Eligibility

Contact Principal Investigator for Information

Study Process

Contact Principal Investigator for Information

Trial Details

Principal Investigator:

Loren Smith, M.D.

IRB:

Willis-Knighton

IRB Number:

12.005

Trial Type:

Drug

Sponsor:

Astra Zenca

Contact Information:

Urology at Pierremont
(318) 212-2840
http://www.urologyatpierremont.com